Daily Biotech Penny Stock Breakdown
Most market participants have been awaiting rotation. Rotation from mega caps into mid-to-small caps and/or rotation back into biotechs.
I am going to start posting daily data on this to confirm or refute rotation has started. This isn’t meant to be presentable. This is just something I run every day and figured I might as well show this publicly.
The penny stock basket contained 369 stocks today (this is as of 3:51pm so the prices may have changed by close.)
The average return was less than the SPY 0.00%↑ returned on the day.
I also monitor all the intraday movers. Here are the top 5 winners and losers. You can see from the charts how easy it to determine when a stock is over or under priced.
Unicycive Therapeutics ($UNCY) was far above the channel and fell on FDA news. This is likely to be an elastic move once the deficiency is cleared.
The FDA communicated to the Company that it had identified deficiencies in cGMP compliance at a third-party manufacturing vendor (one of its CDMO's third-party subcontractors and not its Drug Substance vendor) following an FDA inspection.The FDA indicated that, given the identified deficiencies, any label discussions between the FDA and the Company are precluded. The Company has responded to all FDA information requests and expects a final decision from the FDA by the PDUFA action date of June 28, 2025.
Fractyl Health ($GUTS) was also outside of the channel. There is no direct data released to cause this sell off. Data is due soon.
Elevai Labs ($ELAB) is in the channel. This is retracing after yesterday’s pump. Yesterday’s volume easily eclipsed 10x the total share count. Monitor for an offerings (dots on graphs). If none are flied this could have trapped shorts. NOTE: The SEC defines this is a biotech so it is included in our search. I consider this more a penny stock than a biotech. Letter of Intent is lawyer-speak for bullshit. This looks like it is setting up for something as it was front-run here.
PMGC Holdings Inc. (Nasdaq: ELAB) (the “Company,” “PMGC,” “we,” or “us”), a diversified public holding company, is pleased to announce the signing of a non-binding Letter of Intent (“LOI”) to acquire a U.S.-based, cash-flow positive electronics contract manufacturing company with over 40 years of operational history.
Aethin ($AEMD) reverse split yesterday and sold off today. Our charts have not updated for the reverse split but it was above the channel prior to the RS. The company announced yesterday,
that an abstract has been accepted for poster presentation at the Keystone Symposium on Long COVID and Other Post-Acute Infection Syndromes being held at Eldorado Hotel & Spa, Santa Fe, NM, United States, August 10-13,2025. So there is a potential catalyst coming. This might also setup up a short trap. Need to investigate any warrants existing.
And last X4 Pharmaceuticals which sold off after announcing,
that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to mavorixafor, an oral CXCR4 antagonist, for the treatment of chronic neutropenia (CN). The company is currently conducting a global, pivotal Phase 3 clinical trial (4WARD) evaluating mavorixafor in certain primary CN conditions. Mavorixafor was previously granted Fast Track designation for the treatment of WHIM syndrome, a rare immunodeficiency indication for which it received FDA approval in April 2024.This is likely to be elastic as well.
And on the winners side of life.
Kairos Pharma ($KAPA) is below the RS threshold but above the channel. And this is reporting a gain from spurious price quote. So just a free chart for you. This did not actually fall today.
AbCellera Biologics ($ABCL) was in the channel and riding EM1 for quite awhile before today’s move.
This stock tripped consolidation recently right before the big run so this is most likely investment banking activity or a 3rd party squeezing into the upcoming data. Consolidation is the diamond. (We run a lot of code)
Bone Biologics ($BBLG) was also in the channel. No news to speak of. It recently reverse split (which is not reflected yet) and ran post RS. A few stocks did similarly recently.
Imunon ($IMNN) continued to be elastic even after offering news. Never quite dipped below EM0 in May, but got close.
And lastly, Ironwood Pharmaceuticals ($IRWD) which similar to AbCellera above was riding EM1 and tripped consolidation.
As always, if you think there are spelling errors update your dictionary to the latest version. Happy speculation!
— AJ
We can be found on Twitter.
Or in Chat.
Our charts are updated everyday as new data becomes available and are available via subscription. This is because the costs of doing this analysis across 15,000 securities is not cheap. Compute is not cheap. Neither is the effort required to find these plays before they move. But, it can be done by one person, alone. If you do nothing but read. Every day. So why not use our code instead?
DISCLAIMER: DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS WEBSITE. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. Our website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Past performance is not indicative of future results. The material contained on this page is intended for informational purposes only. GravityAnalytica.com is wholly-owned by Gravity Analytica, LLC. Our website is not an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content of our website and/or newsletter is not provided to any individual with a view toward their individual circumstances. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained on our website is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. We reserve the right to buy or sell shares of any company mentioned on our website or in our newsletter at any time. We encourage you to invest carefully and read investment information available at the websites of the SEC at
and FINRA at
The company or individuals affiliated may hold positions or may enter into, or exit, positions on any equities at any time. This website and materials found on this website, or in any communication, are meant for individuals of eighteen (18) years of age or older and are not suitable for younger audiences. Materials and information provided on this website and in any communications with or from Gravity Analytica LLC, it's employees or affiliates, are for personal education use by subscribers and may be not be used in any regard in competition with this website or any other product or service offered by Gravity Analytica LLC. Past results do not predict future returns. IF YOU DO NOT AGREE WITH THE TERMS OF THIS DISCLAIMER, PLEASE EXIT THIS SITE IMMEDIATELY. PLEASE BE ADVISED THAT YOUR CONTINUED USE OF THIS SITE OR THE INFORMATION PROVIDED HEREIN SHALL INDICATE YOUR CONSENT AND AGREEMENT TO THESE TERMS.